CONTURA INTERNATIONAL A/S — Financial report

CVR 27050832

Latest financial period

  • 2025 • 2025-01-01 • 2025-12-31 • entity • DKK • 311969556 • 185469669 • 70450564 • 59161244 • 536028386 • 232285276 • 127

Financial history

  • 2024 • 2024-01-01 • 2024-12-31 • entity • DKK • 218228040 • 142694438 • 44275781 • 32770236 • 428385425 • 173124032 • 114
  • 2023 • 2023-01-01 • 2023-12-31 • entity • DKK • 179644657 • 98425088 • 32903204 • 19876232 • 295807328 • 140353796 • 83
  • 2022 • 2022-01-01 • 2022-12-31 • entity • DKK • 91821256 • 31172118 • 8314737 • 9705076 • 218145845 • 120477564 • 46
  • 2021 • 2021-01-01 • 2021-12-31 • entity • DKK • 67844659 • 38105107 • 19629564 • 15340391 • 184369901 • 110772488 • 29
  • 2020 • 2020-01-01 • 2020-12-31 • entity • DKK • 61177366 • 23730918 • 7812365 • 6929451 • 141327984 • 95432097 • 22
  • 2019 • 2019-01-01 • 2019-12-31 • entity • DKK • 60161249 • 18762050 • 1473106 • 2444888 • 119801934 • 88502646 • 21
  • 2018 • 2018-01-01 • 2018-12-31 • entity • DKK • 53171092 • 23240874 • 6145030 • 5832747 • 116361403 • 86057755 • 20
  • 2017 • 2017-01-01 • 2017-12-31 • entity • DKK • 47710000 • 21386000 • 4448000 • 3602000 • 93897000 • 80225000 • 20

Annual report highlights

  • primary activities • Business reviewContura International A/S, the Company, develops and manufactures innovative medical products for use within human orthopedics, urology and bowel, and animal health using its unique polyacrylamide hydrogel technology. • entity
  • development in activities and financial affairs • Financial review The company's income statement for the year ended 31 December 2025 shows a profit of DKK 59.161.244, and the balance sheet at 31 December 2025 shows equity of DKK 232.285.276. • entity
  • expected development • Expected development of the Company, including specific prerequisites and uncertaintiesIn 2026, an increase in revenue and gross profit similar to that of 2025 is expected. The Company continues to expect a positive cash flow in 2026. Special risks - operational risks and financial risks: The Company continuously works to identify risks that may affect the Company's future growth, activities, financial position, and results, and seeks to counteract and limit as much as possible the risks that the Company can influence through its actions. Operational risks: The Company's most significant operational risks are related to Manufacturing and Regulatory issues. (1) Manufacturing; Notwithstanding contractual terms to the contrary, contract manufacturers and suppliers used by the Company could cease supply at short notice, resulting in delays in manufacturing, product sales and increased costs. Manufacturing development programmes may encounter delays due to technical problems, for instance in scaling-up manufacturing processes so that commercial quantities of products can be made or growth in sales can be achieved. Third-party manufacturers are subject to regulatory requirements, which may impact on the Company’s development and commercialisation of its products. The Company seeks to mitigate its manufacturing risk, where it is commercially reasonable to do so, by purchasing manufactured goods from more than one source of supply. (2) Regulatory; Regulatory bodies around the world have different requirements for the approval of healthcare products. This may result in restriction of indication, denial of approval, or demands for additional data, particularly in those territories in which approval has not yet been received by the Company. After product approval, safety or efficacy issues may emerge during post-marketing surveillance, which may result in withdrawal or restriction of the product licence. This may have an impact on the growth plans of the Company. The Company seeks to mitigate its regulatory risk by employing expert staff and third party regulatory advisers. Currency risks: The Company's foreign operations are affected by exchange rate fluctuations, as revenue is primarily generated in foreign currency, but a large part of the costs, including salaries, is incurred in Danish kroner. It is the Company’s policy not to hedge currency risks as a general rule, but this is assessed on a case-by-case basis and from currency to currency. Liquidity risks: It is the Company's policy to have credit facilities that are sufficient for the planned activities of the Company. • entity
  • result compared with expectations • Profit/(loss) for the year relative to the expectations most recently expressedPerformance exceeded the expectations set out in the 2024 annual report, driven largely by increased demand for the Company's human orthopedics, urology and bowel, and animal health products. Management considers the year's results satisfactory. • entity
  • recognition measurement uncertainty • Recognition and measurement uncertaintiesThe recognition and measurement of items in the annual report are not associated with any material uncertainties. Management make provisions for doubtful debtors based on the risk of loss due to a customers’ inability to pay, and provisions for obsolescent stock. Raw materials, work in progress, and finished goods are reviewed on a monthly basis, and scrap and obsolescent stock is written off. • entity
  • unusual matters • The company's financial position at 31 December 2025 and the results of its operations for the financial year ended 31 December 2025 are not affected by any unusual matters.For the purpose of ensuring correct classification in the annual financial statements the following classifications have been updated and the comparative figures have been corrected as well. This relates to the following: 1. Other staff costs amounting to DKK 3.949 thousand, were classified as other external costs rather than staff costs. The change in classification has had no impact on the profit for the year, total assets or equity for 2024. 2. Software corresponding to DKK 99 thousand had previously been presented as tangible assets. This has been corrected to intangible assets. The change in classification has had no impact on the profit for the year, total assets or equity for 2024. 3. Development projects relating to software had been classified as tangible assets in the previous year. This has been corrected to intangible assets. The change in classification has no impact on the profit for the year, total assets or equity for 2024. However, the reserve for development costs of DKK 4.885 thousand was not recognised in 2024. This reserve has been updated in 2025 to DKK 12.345 thousand. • entity
  • subsequent events • Significant events occurring after the end of the financial yearNo events have occurred after the balance sheet date which could significantly affect the company's financial position. • entity
  • contingent liabilities • The Company is jointly taxed with its parent Company, Contura A/S, and has limited and secondary liability together with other jointly taxed entities for payment of income taxes as well as for payment of withholding taxes on dividends, interest and royalties. • entity
  • mortgages collateral • The Company has entered into a floating charge over certain of its assets in the amount of DKK 15.000 thousand to secure the borrowings of the Company and the parent Company. • entity